Wellness Clinical Research

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Ulcerative colitis5 trials
• Coeliac disease2 trials
• Crohn's disease2 trials
• Atopic dermatitis (eczema)1 trial
• Migraine1 trial
• Psoriasis1 trial

Phase

• Phase 38 trials
• Phase 24 trials

Status

• Completed5 trials
• Active, not recruiting3 trials
• Recruiting3 trials
• Not yet recruiting1 trial

Lead sponsor

• Eli Lilly and Company5 trials
• Abivax S.A.3 trials
• Takeda2 trials
• Bristol-Myers Squibb1 trial
• Chugai Pharmaceutical1 trial

Running trials

• Recruiting

  Study of DONQ52 in Active Celiac Disease

  NCT07239336· Phase 2· Chugai Pharmaceutical· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

  NCT06979453· Phase 3· Bristol-Myers Squibb· Source

  Contact: David Rodriguez, Site 0014

• Recruiting

  Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

  NCT06456593· Phase 2· Abivax S.A.· Source

  Contact: Lucky Flores, MD

• Recruiting

  A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

  NCT06233461· Phase 2· Takeda· Source

  Contact: Lucky Flores (principal investigator)

• Active, not recruiting

  ABTECT - Maintenance

  NCT05535946· Phase 3· Abivax S.A.· Source

• Active, not recruiting

  A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

  NCT04616326· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

  NCT03519945· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease2 recruiting
• Coeliac disease1 recruiting
• Psoriasis1 recruiting

Closed trials

• Completed

  ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

  NCT05507216· Phase 3· Abivax S.A.· Source

• Completed

  A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

  NCT05353985· Phase 2· Takeda· Source

• Completed

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· Phase 3· Eli Lilly and Company· Source

• Completed

  A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· Phase 3· Eli Lilly and Company· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Eli Lilly and Company· Source